"Transferrin Receptor-Binding Molecules, Conjugates Thereof And Their Uses" in Patent Application Approval Process (USPTO 20230414780).
In: Pharma Business Week, 2024-01-19, S. 1760-1760
serialPeriodical
Zugriff:
This patent application discusses the use of VHH molecules to improve drug delivery to the central nervous system (CNS) by bypassing the blood-brain barrier (BBB). The VHH molecules bind to transferrin receptors on CNS cells, allowing for the transport of therapeutic compounds across the BBB. These conjugate compounds have the potential to be used in the treatment of CNS diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. The patent application provides methods for making these compounds and their use in treating CNS diseases. This information is based on a patent application filed in June 2023 and aims to provide factual news about scientific research and discoveries. [Extracted from the article]
Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Transferrin Receptor-Binding Molecules, Conjugates Thereof And Their Uses" in Patent Application Approval Process (USPTO 20230414780).
|
---|---|
Zeitschrift: | Pharma Business Week, 2024-01-19, S. 1760-1760 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6675 (print) |
Schlagwort: |
|
Sonstiges: |
|